A number of chemotherapeutic agents with anti-cancer activity act as DNA damaging agents, including doxorubicin (DOX), which induces double-strand DNA breaks (DSBs) that activate TP53-mediated cell signaling pathways such as apoptosis, senescence, and cell cycle arrest (Krell et al. 2013; Kruiswijk et al. 2015). This evidence concerns the gene TP53 and cancer.